Research programme: small molecule therapeutics - Pfizer/X-Chem
Latest Information Update: 13 Jun 2014
At a glance
- Originator Pfizer; X-Chem
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Inflammation
Most Recent Events
- 11 Jun 2014 Early research in Inflammation in USA (unspecified route)